CNS NEWS – August 8, 2018: The article highlights that the U.S. Food and Drug Administration signed a new contract on July 25 to acquire “fresh” human fetal tissue to transplant into “humanized mice” so that these mice will have a functioning “human immune system,” according to information published by the FDA and the General Services Administration.
And that: “The objective is to acquire Tissue for Humanized Mice,” said a June 13 FDA “presolicitation notice” for the contract.
The contractor, said the notice, would “provide the human fetal tissue needed to continue the ongoing research being led by FDA.
“Fresh human tissues are required,” said the notice, “for implantation into severely immune-compromised mice to create chimeric animals that have a human immune system.”
“Fetal tissue used in research is obtained from elective abortions,” says the Congressional Research Service.
By issuing a contract to acquire human fetal tissue to use in making mice with human immune systems, the FDA is using federal tax dollars to create a demand for human body parts that must be taken from babies who are aborted. And the FDA would not be able to create the “humanized mice” without fresh tissue taken from aborted babies, and so the FDA also has an interest in the continuation of legalized abortions at a stage in fetal development when the tissue needed to create these mice can be retrieved from the aborted baby.